C-WORTHY: the beginning of the rise of elbasvir and grazoprevir for the treatment of hepatitis C genotype 1 mono and HIV co-infected patients
- PMID: 27867980
- PMCID: PMC5104607
- DOI: 10.21037/atm.2016.09.22
C-WORTHY: the beginning of the rise of elbasvir and grazoprevir for the treatment of hepatitis C genotype 1 mono and HIV co-infected patients
Conflict of interest statement
Dr. Dieterich has served as a speaker as well as consultant for Merck. Dr. Sarpel has no conflicts of interest to declare.
Comment on
-
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.Lancet. 2015 Mar 21;385(9973):1087-97. doi: 10.1016/S0140-6736(14)61793-1. Epub 2014 Nov 11. Lancet. 2015. PMID: 25467560 Clinical Trial.
References
-
- Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012;61:1-32. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources